X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs STRIDES SHASUN LTD - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB STRIDES SHASUN LTD DR. REDDYS LAB/
STRIDES SHASUN LTD
 
P/E (TTM) x 30.2 13.5 223.6% View Chart
P/BV x 3.0 1.6 189.1% View Chart
Dividend Yield % 0.9 0.6 144.4%  

Financials

 DR. REDDYS LAB   STRIDES SHASUN LTD
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
STRIDES SHASUN LTD
Mar-17
DR. REDDYS LAB/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs3,3971,275 266.5%   
Low Rs2,560918 278.9%   
Sales per share (Unadj.) Rs856.5389.6 219.9%  
Earnings per share (Unadj.) Rs78.028.0 278.7%  
Cash flow per share (Unadj.) Rs139.948.9 286.1%  
Dividends per share (Unadj.) Rs20.004.50 444.4%  
Dividend yield (eoy) %0.70.4 163.6%  
Book value per share (Unadj.) Rs739.8303.1 244.1%  
Shares outstanding (eoy) m165.7489.42 185.4%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x3.52.8 123.6%   
Avg P/E ratio x38.239.2 97.5%  
P/CF ratio (eoy) x21.322.4 94.9%  
Price / Book Value ratio x4.03.6 111.3%  
Dividend payout %25.716.1 159.4%   
Avg Mkt Cap Rs m493,63298,036 503.5%   
No. of employees `00022.75.8 391.1%   
Total wages/salary Rs m31,0685,881 528.3%   
Avg. sales/employee Rs Th6,259.06,005.9 104.2%   
Avg. wages/employee Rs Th1,369.81,014.0 135.1%   
Avg. net profit/employee Rs Th569.7431.2 132.1%   
INCOME DATA
Net Sales Rs m141,96134,834 407.5%  
Other income Rs m1,7151,686 101.7%   
Total revenues Rs m143,67636,520 393.4%   
Gross profit Rs m24,7226,428 384.6%  
Depreciation Rs m10,2661,872 548.5%   
Interest Rs m6342,269 27.9%   
Profit before tax Rs m15,5373,973 391.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m3494 9,694.4%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m2,965470 630.9%   
Profit after tax Rs m12,9212,501 516.7%  
Gross profit margin %17.418.5 94.4%  
Effective tax rate %19.111.8 161.3%   
Net profit margin %9.17.2 126.8%  
BALANCE SHEET DATA
Current assets Rs m96,83738,165 253.7%   
Current liabilities Rs m84,19930,402 277.0%   
Net working cap to sales %8.922.3 39.9%  
Current ratio x1.21.3 91.6%  
Inventory Days Days7377 94.9%  
Debtors Days Days98104 93.5%  
Net fixed assets Rs m102,55237,639 272.5%   
Share capital Rs m829894 92.7%   
"Free" reserves Rs m121,79226,210 464.7%   
Net worth Rs m122,62127,105 452.4%   
Long term debt Rs m5,44916,377 33.3%   
Total assets Rs m218,16581,168 268.8%  
Interest coverage x25.52.8 927.2%   
Debt to equity ratio x00.6 7.4%  
Sales to assets ratio x0.70.4 151.6%   
Return on assets %6.25.9 105.7%  
Return on equity %10.59.2 114.2%  
Return on capital %12.912.1 107.0%  
Exports to sales %54.60-   
Imports to sales %9.40-   
Exports (fob) Rs m77,520NA-   
Imports (cif) Rs m13,274NA-   
Fx inflow Rs m81,67013,465 606.5%   
Fx outflow Rs m26,3554,076 646.6%   
Net fx Rs m55,3159,389 589.1%   
CASH FLOW
From Operations Rs m21,4442,881 744.2%  
From Investments Rs m-18,404-7,051 261.0%  
From Financial Activity Rs m-3,6923,382 -109.2%  
Net Cashflow Rs m-1,144-788 145.3%  

Share Holding

Indian Promoters % 25.5 27.7 92.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 37.8 14.3%  
FIIs % 35.3 8.6 410.5%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 25.9 59.1%  
Shareholders   75,885 56,241 134.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   PANACEA BIOTECH  BIOCON LTD  VENUS REMEDIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Firm; IT Stocks Gain(09:30 am)

Asian stocks were relatively subdued in the early trade today, with most regional indices hovering around the flat line following the softer lead stateside.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Feb 21, 2018 10:49 AM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS